Drug Profile
Research programme: K-ras gene therapies - Introgen/sanofi-aventis
Alternative Names: Antisense K-ras gene therapy -Introgen Therapeutics; IGN-111; RV-AS-K-RASLatest Information Update: 04 Mar 2008
Price :
$50
*
At a glance
- Originator Introgen Therapeutics
- Class Antineoplastics; Gene therapies
- Mechanism of Action Ras gene inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 31 Aug 2004 Aventis has merged with Sanofi-Synthélabo to form sanofi-aventis
- 04 Jul 2002 This programme is still in active development
- 24 Dec 1999 Rhône-Poulenc Rorer Gencell is now called Aventis Gencell